Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma - Report - MDSpire

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

  • By

  • Karan L. Chohan

  • Rina L. Welkie

  • James Godfrey

  • Steven Bair

  • Lorenzo Falchi

  • Manali Kamdar

  • Ajay Major

  • Wendy Dixon

  • Jennifer Crombie

  • Reid Merryman

  • Sonia Godbole

  • Gilles Salles

  • Omnia Farahat

  • Amy Ayers

  • Ayushi Chauhan

  • Alex Herrera

  • Geoffrey Shouse

  • Sairah Ahmed

  • Yazeed Sawalha

  • May 22, 2026

  • 0 min

Share

Clinical Report: Outcomes of CD3xCD20 Bispecific Antibodies in Patients with Lymphoma Affecting the Central Nervous System

Overview

This multicenter retrospective study evaluates the efficacy and safety of CD3xCD20 bispecific antibodies (BsAbs) in patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL) with active or prior central nervous system (CNS) involvement. The study reports a 56% overall response rate and a 65% CNS-specific response rate among treated patients.

Background

Central nervous system involvement in aggressive B-NHL poses significant treatment challenges and is associated with poor outcomes. While CAR T-cell therapy has shown promise, its effectiveness is often limited by short-lived responses. The role of CD3xCD20 BsAbs in this patient population remains underexplored.

Data Highlights

CharacteristicValue
Overall Response Rate (ORR)56% (10/18)
Complete Response (CR)33% (6/18)
CNS ORR65% (11/17)
Median Age68 years
Median Lines of Prior Therapy3

Key Findings

  • 56% overall response rate (ORR) observed in patients with active CNS involvement.
  • 33% of patients achieved a complete response (CR).
  • 65% CNS-specific ORR noted among evaluable patients.
  • Median age of patients at treatment initiation was 68 years.
  • Prior to BsAb therapy, patients had a median of 3 lines of therapy.

Clinical Implications

Understanding the safety profile in this population is crucial for optimizing treatment strategies.

Conclusion

The findings from this study provide evidence of the efficacy of CD3xCD20 bispecific antibodies in patients with CNS involvement due to aggressive B-NHL.

Related Resources & Content

  1. Blood Cancer Journal, 2021 -- Combination CD19/22 CAR T-cell therapy after autologous stem cell transplantation for central nervous system lymphoma
  2. The ASCO Post, 2021 -- Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
  3. The ASCO Post, 2025 -- NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma
  4. Blood Cancer Journal, 2024 -- Current Insights and Future Directions on Bi- and Tri-specific Antibodies for Non-Hodgkin Lymphoma
  5. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - PMC
  6. Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial - PMC
  7. Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma - ScienceDirect
  8. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - PMC
  9. Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial - PMC
  10. Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma - ScienceDirect

Original Source(s)

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

  • by Karan L. Chohan, Rina L. Welkie, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Wendy Dixon, Jennifer Crombie, Reid Merryman, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

  • May 22, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review